Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine (Vidaza) in pediatric high‑grade MDS or JMML
DRKS00005375Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) (5 arms), sponsored by Erasmus MC. Started Nov 2013; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on DRKS00005375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005375.